{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:43:55Z","timestamp":1789670635742,"version":"4.0.1"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Breast cancer is a common malignancy among women, with triple-negative breast cancer (TNBC) representing a subtype with poor prognosis. Due to the lack of expression of targetable receptors, traditional hormone therapy and HER2-targeted therapy are ineffective against TNBC. Moreover, TNBC typically exhibits more aggressive biological behavior, with a high propensity for recurrence and metastasis, further exacerbating its poor prognosis. While chemotherapy remains the primary treatment modality, its efficacy is limited, and patients readily develop resistance. Consequently, exploring novel therapeutic strategies and targets is crucial for improving the prognosis of patients with TNBC. Tumor-infiltrating lymphocytes (TILs) are promising prognostic and predictive biomarkers of TNBC. Multiple studies have demonstrated that a higher number of TILs in early-stage TNBC is correlated with favorable outcomes. Furthermore, clinical trials have demonstrated that TIL therapy is effective in solid tumors. This review outlines the current understanding of the TIL role in TNBC, elucidates the mechanisms and clinical efficacy of TIL therapy, and discusses future research directions and challenges for TILs.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1741333","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:51:38Z","timestamp":1772175098000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor-infiltrating lymphocyte therapy in triple-negative breast cancer: from mechanistic exploration to clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Yongxi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2023.04.002","article-title":"Molecular classification of breast cancer","volume":"18","author":"Roy","year":"2023","journal-title":"PET Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27581","article-title":"Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomized phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/cancers17040633","article-title":"Triple-negative breast cancer systemic treatment: disruptive early-stage developments for overcoming stagnation in the advanced pipeline","volume":"17","author":"Alonso-Ron","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.3390\/ijms26062716","article-title":"The role\u00a0of\u00a0the\u00a0tumor microenvironment (TME) in advancing cancer therapies: immune\u00a0system interactions, tumor-infiltrating lymphocytes (TILs), and the role of exosomes and inflammasomes","volume":"26","author":"Erasha","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.387","article-title":"Tumor resident mesenchymal stromal cells endow na\u00efve stromal cells with tumor-promoting properties","volume":"33","author":"Ren","year":"2014","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e010928","DOI":"10.1136\/jitc-2024-010928","article-title":"Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols","volume":"13","author":"Cottrell","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13058-024-01932-4","article-title":"Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer","volume":"26","author":"Han","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-022-02340-2","article-title":"The role of tumor-infiltrating lymphocytes in cholangiocarcinoma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1399754","article-title":"Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches","volume":"15","author":"Naji","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.3390\/cancers15184479","article-title":"Tumor infiltrating lymphocytes (TILS) and PD-L1 expression in breast cancer: A review of current evidence and prognostic implications from pathologist\u2019s perspective","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1153990","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1302587","article-title":"Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics","volume":"15","author":"Akinsipe","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes (TILs) in breast cancer: prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The great immune escape: understanding the divergent immune response in breast cancer subtypes","volume":"13","author":"Onkar","year":"2023","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.3390\/ijms21186968","article-title":"CD8 T cell score as a prognostic biomarker for triple negative breast cancer","volume":"21","author":"Oshi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1038\/s41467-018-06653-9","article-title":"Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression","volume":"9","author":"Egelston","year":"2018","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ccell.2023.01.004","article-title":"Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer","volume":"41","author":"Virassamy","year":"2023","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00795-017-0170-y","article-title":"Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer","volume":"50","author":"Kurozumi","year":"2017","journal-title":"Med Mol Morphol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.01.001","article-title":"Breast cancer tumor microenvironment affects Treg\/IL-17-producing Treg\/Th17 cell axis: Molecular and therapeutic perspectives","volume":"28","author":"Seif","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of TH cells: A balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/2326-6066.CIR-22-0426","article-title":"Hedgehog signaling regulates Treg to Th17 conversion through metabolic rewiring in breast cancer","volume":"11","author":"Hinshaw","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1194020","article-title":"The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2021.03.005","article-title":"Tumor infiltrating lymphocytes in oropharyngeal carcinoma: prognostic value and evaluation of a standardized method","volume":"53","author":"Keukeleire","year":"2021","journal-title":"Pathology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.109","article-title":"Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group","volume":"29","author":"Denkert","year":"2016","journal-title":"Modern Pathology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41523-020-0154-2","article-title":"Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group","volume":"6","author":"Amgad","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02730-6","article-title":"Quantitative digital image analysis of tumor-infiltrating lymphocytes in HER2-positive breast cancer","volume":"476","author":"Abe","year":"2020","journal-title":"Virchows Arch"},{"key":"B32","doi-asserted-by":"publisher","first-page":"105095","DOI":"10.1016\/j.esmoop.2025.105095","article-title":"Multi-assistant methods improve stromal tumor-infiltrating lymphocytes (sTILs) assessment in breast cancer: results of multi-institutional ring studies","volume":"10","author":"Zhao","year":"2025","journal-title":"ESMO Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-020-01378-4","article-title":"Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer","volume":"23","author":"Sanchez","year":"2021","journal-title":"Breast Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: A pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"JCO"},{"key":"B35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumor-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01536","article-title":"Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)Adjuvant systemic therapy","volume":"40","author":"De Jong","year":"2022","journal-title":"JCO"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy547","article-title":"Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy","volume":"30","author":"Luen","year":"2019","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt556","article-title":"Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study","volume":"25","author":"Dieci","year":"2014","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3863-3","article-title":"Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00","volume":"158","author":"Pruneri","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv239","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials","volume":"26","author":"Dieci","year":"2015","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.072","article-title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study","volume":"31","author":"Schmid","year":"2020","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41523-024-00683-x","article-title":"Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502","volume":"10","author":"Stover","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-PD5-03","article-title":"Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)","volume":"80","author":"Loi","year":"2020","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158","article-title":"A randomized phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"Loibl","year":"2019","journal-title":"Ann Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"17588359241240304","DOI":"10.1177\/17588359241240304","article-title":"A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer","volume":"16","author":"Liu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1551583","article-title":"Cell-based immunotherapies for solid tumors: advances, challenges, and future directions","volume":"15","author":"Zhao","year":"2025","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"A preliminary Rep N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.11.004","article-title":"Tumor infiltrating lymphocytes streamlining a complex manufacturing process","volume":"21","author":"Hopewell","year":"2019","journal-title":"Cytotherapy"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e000848","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"van den Berg","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2013small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov"},{"key":"B57","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s10238-025-01574-6","article-title":"Tumor infiltration therapy: from FDA approval to next-generation approaches","volume":"25","author":"Shaik","year":"2025","journal-title":"Clin Exp Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2011.12.004","article-title":"Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures","volume":"273","author":"Junker","year":"2012","journal-title":"Cell Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e003499","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.02.004","article-title":"Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor","volume":"16","author":"Donia","year":"2014","journal-title":"Cytotherapy"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1158\/1078-0432.CCR-16-1423","article-title":"Characterization of an immunogenic mutation in a patient with metastatic triple-negative breast cancer","volume":"23","author":"Assadipour","year":"2017","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Huq","year":"2022","journal-title":"JCO"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL therapy: facts and hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarr\u00e1n","year":"2024","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/CJI.0000000000000495","article-title":"Core needle biopsies as an alternative source for ex vivo expanded TIL for adoptive cell therapy in triple-negative breast cancer","volume":"47","author":"Coman","year":"2024","journal-title":"J Immunother"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen\u2013specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907448106","article-title":"Adoptively transferred effector cells derived from na\u00efve rather than central memory CD8+ T cells mediate superior antitumor immunity","volume":"106","author":"Hinrichs","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446","article-title":"A human memory T-cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00263","article-title":"Fueling cancer immunotherapy with common gamma chain cytokines","volume":"10","author":"Dwyer","year":"2019","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-016-0160-z","article-title":"T cell exhaustion: from pathophysiological basics to tumor immunotherapy","volume":"15","author":"Catakovic","year":"2017","journal-title":"Cell Commun Signal"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00323-0","article-title":"The CD28 signaling pathway regulates glucose metabolism","volume":"16","author":"Frauwirth","year":"2002","journal-title":"Immunity"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645242","article-title":"Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy","volume":"12","author":"Rangel Rivera","year":"2021","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K\u03b4 inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01221","article-title":"PI3K\u03b4 Inhibition enhances the antitumor fitness of adoptively transferred CD8+ T cells","volume":"8","author":"Bowers","year":"2017","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ebiom.2016.01.019","article-title":"Modulation of mTOR signaling triggers the formation of stem cell-like memory T cells","volume":"4","author":"Scholz","year":"2016","journal-title":"eBioMedicine"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e20107","DOI":"10.1371\/journal.pone.0020107","article-title":"Characterization of the metabolic phenotype of rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells","volume":"6","author":"He","year":"2011","journal-title":"PloS One"},{"key":"B79","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2020.05.004","article-title":"Multi-phenotype CRISPR-cas9 screen identifies p38 kinase as a target for adoptive immunotherapies","volume":"37","author":"Gurusamy","year":"2020","journal-title":"Cancer Cell"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69589","article-title":"Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-0256-z","article-title":"Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy","volume":"2","author":"Geltink","year":"2020","journal-title":"Nat Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1741333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:51:39Z","timestamp":1772175099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1741333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":82,"alternative-id":["10.3389\/fimmu.2026.1741333"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1741333","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1741333"}}